These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29597186)

  • 21. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.
    Leierer J; Perco P; Hofer B; Eder S; Dzien A; Kerschbaum J; Rudnicki M; Mayer G
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Podocyte Injury in Autosomal Dominant Polycystic Kidney Disease.
    Cebeci E; Ekinci I; Gursu M; Coskun C; Karadag S; Uzun S; Behlul A; Senel TE; Kazancioglu R; Ozturk S
    Nephron; 2019; 142(4):311-319. PubMed ID: 31117091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocan, TGF-beta, and ADMA as Risk Factors for Endothelial Dysfunction and Possible Vascular Disease in Patients with Subclinical Hypothyroidism.
    Arpaci D; Karakece E; Tocoglu AG; Ergenc H; Gurol G; Ciftci IH; Tamer A
    Ann Clin Lab Sci; 2016 Dec; 46(6):601-607. PubMed ID: 27993872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
    Heffernan KS; Kuvin JT; Sarnak MJ; Perrone RD; Miskulin DC; Rudym D; Chandra P; Karas RH; Menon V
    Nephrol Dial Transplant; 2011 Aug; 26(8):2515-21. PubMed ID: 21292815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelial dysfunction and oxidative stress in polycystic kidney disease.
    Klawitter J; Reed-Gitomer BY; McFann K; Pennington A; Klawitter J; Abebe KZ; Klepacki J; Cadnapaphornchai MA; Brosnahan G; Chonchol M; Christians U; Schrier RW
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1198-206. PubMed ID: 25234311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL; Wang W; Farmer-Bailey H; Gitomer B; Malaczewski M; Klawitter J; Jovanovich A; Chonchol M
    Clin J Am Soc Nephrol; 2018 Oct; 13(10):1493-1501. PubMed ID: 30228110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiopoietin-2 outperforms other endothelial biomarkers associated with severe acute kidney injury in patients with severe sepsis and respiratory failure.
    Yu WK; McNeil JB; Wickersham NE; Shaver CM; Bastarache JA; Ware LB
    Crit Care; 2021 Feb; 25(1):48. PubMed ID: 33541396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Smoking on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease Patients with Preserved Renal Function.
    Gul CB; Yildiz A; Sag S; Oruc A; Ersoy A; Gullulu S
    Ren Fail; 2021 Dec; 43(1):1124-1129. PubMed ID: 34256663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocan Concentration in Kidney Transplant Recipients.
    Malyszko J; Koc-Żórawska E; Malyszko JS
    Transplant Proc; 2018; 50(6):1798-1801. PubMed ID: 30056903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease.
    Lai S; Mastroluca D; Matino S; Panebianco V; Vitarelli A; Capotosto L; Turinese I; Marinelli P; Rossetti M; Galani A; Baiocchi P; D'Angelo AR; Palange P
    Kidney Blood Press Res; 2017; 42(6):1290-1302. PubMed ID: 29262409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenesis in autosomal-dominant polycystic kidney disease.
    Bello-Reuss E; Holubec K; Rajaraman S
    Kidney Int; 2001 Jul; 60(1):37-45. PubMed ID: 11422734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease.
    Ozkurt S; Dogan I; Ozcan O; Fidan N; Bozaci I; Yilmaz B; Bilgin M
    Int Urol Nephrol; 2019 Jul; 51(7):1191-1197. PubMed ID: 31012038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients.
    Palud A; Parmentier-Decrucq E; Pastre J; De Freitas Caires N; Lassalle P; Mathieu D
    Cytokine; 2015 Jun; 73(2):213-8. PubMed ID: 25794660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor-β1 in Autosomal Dominant Polycystic Kidney Disease Patients.
    Kocer D; Karakukcu C; Ozturk F; Eroglu E; Kocyigit I
    Ther Apher Dial; 2016 Oct; 20(5):517-522. PubMed ID: 26991810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.